OmegaGenesis has achieved a number of significant scientific and
application development advantages resulting from advanced
research. This research has provided the discovery and processes
essential to producing the core nano-materials required to invoke
angiogenesis and anti-angiogenesis applications.
OmegaGenesis has discovered and refined the formation of the nano-materials and production process for a number of elements to invoke angiogenesis and anti-angiogenesis. OmegaGenesis has a license agreement in place for the patented Angiogenesis discovery by a leading medical research center and plans to collaborate in the testing and research work.
The product development process is designed to produce suitable nano-materials to manage human body functions at nano scale - the cell and sub-cell level -- accelerating cellular-based biologic therapies. These nano-materials will enable doctors to treat disease at sub-cell level in a targeted manner instead of treating the disease at the organ or tissue level.
The important research step of nano-material property and toxicity effect has been established. We have successfully lab and animal tested angiogenesis potential effect. We are in process of completing testing for imaging. This testing is underway with rare earth nano-materials.
Moreover, we are collaborating and completing the analysis on Gold-nano particle for anti-angiogenesis applications.
Our most significant advantage is the acceleration of product development based on the core nano-material research, formation, and nano-material toxicity and effect testing. It is now possible to look inside a cell to stimulate the organic growth of blood cells in constructive conditions or inhibit the expansion of blood cells to stop destructive growth.
We have seven patentable application plans in progress. Our application development plans are in angiogenesis, anti-angiogenesis and imaging areas. Additionally we are investigating several of materials for drug delivery and diagnostic applications.
OmegaGenesis has moved forward the product development process with the preparation and comprehensive plan to conduct both animal and clinical tests in about one-third of the time commonly required. Preparation for both animal and clinical tests is an area that contributes to success of any product and application and often consider as critical as the technology itself. OmegaGenesis is actively pursuing clinical trials in India to accelerate the process and reduce the cost of development cycle.
Our mission emphasizes collaborative research with leading medical centers and universities followed by rapid product design, development, and validation. OmegaGenesis collaborates with academic research centers, corporate research partners and is actively exploring international research partnerships.
| 1 | Material Discovery and Formation |
OmegaGenesis has discovered and refined the formation of the nano-materials and production process for a number of elements to invoke angiogenesis and anti-angiogenesis. OmegaGenesis has a license agreement in place for the patented Angiogenesis discovery by a leading medical research center and plans to collaborate in the testing and research work.
The product development process is designed to produce suitable nano-materials to manage human body functions at nano scale - the cell and sub-cell level -- accelerating cellular-based biologic therapies. These nano-materials will enable doctors to treat disease at sub-cell level in a targeted manner instead of treating the disease at the organ or tissue level.
| 2 | Nano-material Toxicity and Effect Testing |
The important research step of nano-material property and toxicity effect has been established. We have successfully lab and animal tested angiogenesis potential effect. We are in process of completing testing for imaging. This testing is underway with rare earth nano-materials.
Moreover, we are collaborating and completing the analysis on Gold-nano particle for anti-angiogenesis applications.
| 3 | Applications Development Based on Discovered Effects |
Our most significant advantage is the acceleration of product development based on the core nano-material research, formation, and nano-material toxicity and effect testing. It is now possible to look inside a cell to stimulate the organic growth of blood cells in constructive conditions or inhibit the expansion of blood cells to stop destructive growth.
We have seven patentable application plans in progress. Our application development plans are in angiogenesis, anti-angiogenesis and imaging areas. Additionally we are investigating several of materials for drug delivery and diagnostic applications.
| 4 | Trial Advantages |
OmegaGenesis has moved forward the product development process with the preparation and comprehensive plan to conduct both animal and clinical tests in about one-third of the time commonly required. Preparation for both animal and clinical tests is an area that contributes to success of any product and application and often consider as critical as the technology itself. OmegaGenesis is actively pursuing clinical trials in India to accelerate the process and reduce the cost of development cycle.
| 5 | Global Collaboration Partners |
Our mission emphasizes collaborative research with leading medical centers and universities followed by rapid product design, development, and validation. OmegaGenesis collaborates with academic research centers, corporate research partners and is actively exploring international research partnerships.